Concept Foundation is happy to announce that Incepta Pharmaceuticals (Bangladesh) has been awarded WHO Prequalification of their intramuscular (IM) depot medroxyprogesterone acetate (DMPA) 150 mg/ml product.
A third quality assured, generic DMPA-IM contraceptive product available for procurement
New beginnings @ConceptFNDN When I started working on the heat stable carbetocin project in 2012 at the Special Programme of Research on Human Reproduction (HRP), a public private partnership between WHO/HRP, Ferring Pharmaceuticals and MSD for Mothers I was...
The Evidence for Contraceptive Options and HIV Outcomes (ECHO) trial results have been released, finally providing long awaited answers to questions about the relationship between DMPA, the Implant and the Copper IUD and risk of HIV transmission in women.
Access to Quality Assured generic Intramuscular DMPA continues to rise
Mylan Laboratories Limited has received a risk category 1 ranking from the WHO Expert Review Panel for its generic injectable, medroxyprogesterone acetate depot 150mg/ml.
The first generic two-rod sub-dermal levonorgestrel 75mg implant product has received a positive result from the Expert Review Panel (ERP), making it the first of its kind to reach the quality standard for international procurement.
Concept Foundation is pleased to announce that India’s Drugs Technical Advisory Board recently agreed to the introduction of Depot-medroxyprogesterone acetate, or DMPA, under the National Family Planning Programme.
The Bill & Melinda Gates Foundation awards Concept Foundation with a grant to continue and expand upon work initiated under QuRHM for DMPA.